Skip to search formSkip to main contentSkip to account menu

evofosfamide

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

TH 302

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Molecular correlation of the activity of evofosfamide (EVO) in combination with sunitinib (SUN) in pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial.
e16706Background: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and… 
2019
2019
SUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish task force group for…
Abstract Background Sunitinib (SUN) is approved for the treatment of advanced progressive pNETs. Hypoxia induced by SUN could… 
2018
2018
Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study.
2568Background: Evofosfamide (Evo) is a prodrug of Br-IPM that is preferentially activated under hypoxic conditions. Hypoxia in… 
2016
2016
Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in…
Purpose: This phase 1/2 study was conducted to determine the maximum tolerated dose (MTD), safety, tolerability, and clinical… 
2016
2016
A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic…
TPS479 Background: Pancreatic-NETs are highly vascular tumors. The anti-angiogenetic sunitinib was approved in advanced pNETs… 
2016
2016
Abstract 2803: Distinct roles of intracellular ROS in cisplatin and evofosfamide cytotoxicity
Cisplatin is one of the most widely used anticancer agents for the treatment of an array of malignancies. Although multiple… 
2015
2015
Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple…
8579 Background: The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma (MM… 
2015
2015
A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.
TPS9089 Background: In melanoma, tumor hypoxia is associated with invasion, angiogenesis, and metastasis formation, as well as… 
2015
2015
DNA repair processes involved with the hypoxia-activated prodrug evofosfamide (TH-302): comparison to cisplatin and temozolomide
Vasquez et al. Targeting and processing of site-specific DNA interstrand crosslinks. Env and Mol Mut 51: 527-339, 2010 Wang et al… 
2015
2015
Evofosfamide Fails to Extend Survival in Soft-Tissue Sarcoma, Pancreatic Cancer
The developer of evofosfamide announced that two phase III trials of the agent in advanced soft-tissue sarcoma and in advanced… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)